Cargando…
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
INTRODUCTION: Hemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal immunoglobulin for intravenous administration [i.e., intravenous immunoglobulin (IVIG)]. Anti-A/B isoagglutinins (also referred to as isohemagglutinins) originating from d...
Autores principales: | Siani, Brigitte, Willimann, Katharina, Wymann, Sandra, Marques, Adriano A., Widmer, Eleonora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254866/ https://www.ncbi.nlm.nih.gov/pubmed/24841428 http://dx.doi.org/10.1007/s13554-014-0016-2 |
Ejemplares similares
-
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
por: Gerber, Simon, et al.
Publicado: (2016) -
Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study
por: Wallenhorst, Christopher, et al.
Publicado: (2020) -
Successful ABO-incompatible living donor liver transplantation using splenectomy and intravenous immunoglobulin in high isoagglutinin titer patients
por: Lee, Boram, et al.
Publicado: (2020) -
APPEARANCE OF ISOAGGLUTININS IN INFANTS AND CHILDREN
por: Happ, W. M.
Publicado: (1920) -
Clinical Relevance of Isoagglutinin Rebound in Adult ABO-Incompatible Living Donor Liver Transplantation
por: Lee, Wei-Chen, et al.
Publicado: (2021)